Document Detail

Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
MedLine Citation:
PMID:  16918265     Owner:  NLM     Status:  MEDLINE    
A low-density lipoprotein (LDL) cholesterol goal of less than 100 mg/dl is recommended for patients at moderate to high risk of cardiovascular disease with an optional LDL goal of less than 70 mg/dl for patients at a very high risk of cardiovascular disease. Most patients will require reductions in LDL of more than 50% in order to achieve these more aggressive goals. Only a few agents will lower LDL by at least 50%. This review will focus on the efficacy and safety ezetimibe/simvastatin coadministered as a therapy with enhanced LDL-lowering efficacy, while minimizing the adverse effects of statins in a wide range of patients. Ezetimibe 10 mg/simvastatin 80 mg lowers LDL by approximately 60% and has been demonstrated to be superior to the highest doses of atorvastatin and rosuvastatin for lowering LDL and raising high-density lipoprotein.
Jennifer G Robinson; Michael H Davidson
Related Documents :
22906275 - Evaluation of the significance of circulating insulin-like growth factor-1 and c-reacti...
21574895 - Long-term use of fenofibrate is associated with increased prevalence of gallstone disea...
21764635 - Awaji als criteria increase the diagnostic sensitivity in patients with bulbar onset.
22443505 - Hyperacute cerebral aneurysm rerupture during ct angiography.
19576595 - Hyperdense middle cerebral artery sign and outcome after intravenous thrombolysis for a...
2210085 - Diagnostic features and clinical signs of 21 patients with lissencephaly type 1.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  4     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-08-21     Completed Date:  2006-10-06     Revised Date:  2006-11-22    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  461-76     Citation Subset:  IM    
University of Iowa, Lipid Research Clinic, Departments of Epidemiology & Medicine, 200 Hawkins Drive, SE 226 GH, Iowa City, IA 52242, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticholesteremic Agents / administration & dosage,  therapeutic use*
Azetidines / administration & dosage,  metabolism,  pharmacology,  therapeutic use*
C-Reactive Protein / analysis,  drug effects
Cardiovascular Diseases / blood,  prevention & control
Drug Therapy, Combination
Heptanoic Acids / administration & dosage,  pharmacology,  therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage,  therapeutic use*
Hypercholesterolemia / blood,  drug therapy
Intestinal Absorption / drug effects,  physiology
Lipoproteins, LDL / blood,  drug effects*
Phytosterols / blood
Pravastatin / administration & dosage,  pharmacology,  therapeutic use
Pyrroles / administration & dosage,  pharmacology,  therapeutic use
Simvastatin / administration & dosage,  metabolism,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Azetidines; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipoproteins, LDL; 0/Phytosterols; 0/Pyrroles; 110862-48-1/atorvastatin; 163222-33-1/ezetimibe; 79902-63-9/Simvastatin; 81093-37-0/Pravastatin; 9007-41-4/C-Reactive Protein
Erratum In:
Expert Rev Cardiovasc Ther. 2006 Sep;4(5):772

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
Next Document:  Weighing in on molecular anchors: the role of ankyrin polypeptides in human arrhythmia.